Somali C Gavane, MD

Clinical Focus

• Alzheimer's Disease
• Cancer
• Lung Cancer
• PET/CT Scan
• Radiology

• Alzheimer's Disease
• Cancer
• Lung Cancer
• PET/CT Scan
• Radiology

Research

Locations

Mount Sinai Nuclear Medicine

1190 Fifth Ave., MC Level, New York, NY, 10029

212-241-6611

Radiology Associates

One Gustave L Levy Place, Box 1141, NYC, NY, 10029

212-241-6549

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:10

Article:16

Chapter:8

Recent Artifacts

• ¹⁸F-FDG and ¹⁸F-Fluciclovine Uptake in Poorly Differentiated Lung Adenocarcinoma in the Setting of Biochemically Recurrent Prostatic Adenocarcinoma
• FDG-PET/MRI for the preoperative diagnosis and staging of peritoneal carcinomatosis: a prospective multireader pilot study
• Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
• Asymptomatic SARS-CoV-2 infection: Incidental findings on FDG PET/CT
• Predicting malignancy in patients with adrenal tumors using ¹⁸F-FDG-PET/CT SUVmax
• PET in Lymphoma
• Feasibility and feasibility and diagnostic performance of hybrid pet/mri compared with pet/ct for gynecological malignancies: A prospective pilot study
• Positron emission tomography/computed tomography-based assessments of androgenreceptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer
• Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
• Teaching cases in nuclear oncology: Testicular cancer

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Gavane did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.